Abstract

BACKGROUND AND PURPOSE-: Animal data suggest the use of β-human chorionic gonadotropin followed by erythropoietin to promote brain repair after stroke. The current study directly translated these results by evaluating safety of this sequential growth factor therapy through a 3-center, single-dose, open-label, noncontrolled, Phase IIa trial. METHODS-: Patients with ischemic stroke 24 to 48 hours old and National Institutes of Health Stroke Scale score of 6 to 24 started a 9-day course of β-human chorionic gonadotropin followed by erythropoietin. This study also evaluated performance of serially measured domain-specific end points. RESULTS-: A total of 15 patients were enrolled. Two deaths occurred, neither related to study medications. No safety concerns were noted among clinical or laboratory measures, including screening for deep vein thrombosis and serial measures of serum hemoglobin. In several instances, domain-specific end points provided greater insight into impairments as compared with global outcome measures. CONCLUSIONS-: Results support the safety of this sequential, 2-growth factor therapy initiated 24 to 48 hours after stroke onset. © 2010 American Heart Association, Inc.